Results 241 to 250 of about 91,276 (376)
Nitric oxide induces decomposition of electron‐deficient aminoferrocene drugs 4 with formation of oxime 7, which is derived from the upper cyclopentadienyl ligand. Drugs 4 are not responsive to hydrogen peroxide. Based on the latter reaction, the fluorogenic probes are developed for detecting NO in cells and inflammation in vivo.
Roman Selin +4 more
wiley +1 more source
No evidence of molecular markers of piperaquine resistance in southeastern Nigeria. [PDF]
Ikegbunam M +6 more
europepmc +1 more source
Antimalarial Activity of 77 Phospholipid Polar Head Analogs: Close Correlation Between Inhibition of Phospholipid Metabolism and In Vitro Plasmodium Falciparum Growth [PDF]
Marie‐Laure Ancelin +8 more
openalex +1 more source
Novel C1'‐branched acyclic nucleoside phosphonates were synthesized. The compounds are inhibitors of Plasmodium falciparum and human 6‐oxopurine phosphoribosyltransferases with Ki values as low as 0.4 µM and 0.7 µM, respectively. A phosphonodiamidate prodrug exhibited IC50 = 4.3 µM against a drug‐sensitive strain of P.
Jan Frydrych +11 more
wiley +1 more source
Antimalarial compounds exhibit variant- and cell-type-specific activity against SARS-CoV-2 isolated in Panama. [PDF]
Quijada M +12 more
europepmc +1 more source
The Plasmodium falciparum Translationally Controlled Tumor Protein Homolog and Its Reaction with the Antimalarial Drug Artemisinin [PDF]
Jamaree Bhisutthibhan +7 more
openalex +1 more source
Translation of a Human‐Based Malaria‐on‐a‐Chip Phenotypic Disease Model for In Vivo Applications
Inoculation of the Malaria‐on‐a‐Chip model with human erythrocytes infected with Plasmodium falciparum can support the entire intraerythrocytic lifecycle for 7 days in vitro. Utilizing this human‐based, serum‐free model provides an alternative to animal testing by introducing a human‐based, preclinical alternative for antimalarial therapeutic delivery.
Michael J. Rupar +15 more
wiley +1 more source

